Streetbeat News

Stock Prices

SCL

Stepan (NYSE:SCL) reported Q2 2024 adjusted EPS of $0.41, missing the $0.67 estimate by 38.81%. Sales were $556.405M, missing the $589.800M estimate by 5.66% and down 4.06% from last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:12 am

COCO

Vita Coco (NASDAQ:COCO) reported Q2 earnings per share of $0.32, beating the analyst estimate of $0.29. Sales were $144.12 million, slightly above the $143.96 million estimate. Both earnings and sales showed year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:10 am

WEC

WEC Energy has affirmed its FY24 GAAP EPS guidance of $4.80-$4.90, which is in line with the $4.88 estimate.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:10 am

WEC

WEC Energy Group (NYSE:WEC) reported Q2 2024 earnings per share (EPS) of $0.67, beating the analyst estimate of $0.63. However, sales of $1.770 billion missed the estimate of $1.866 billion. EPS decreased by 27.17% year-over-year, and sales decreased by 3.28% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:09 am

DAY

Dayforce shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY24 revenue guidance above estimates.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:09 am

CBZ

CBIZ (NYSE:CBZ) reported Q2 adjusted EPS of $0.50, missing the $0.68 estimate, and sales of $420.01M, missing the $430.38M estimate. EPS decreased by 9.09% YoY, while sales increased by 5.40% YoY.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:09 am

FULC

Fulcrum Therapeutics (NASDAQ:FULC) reported Q2 earnings of $0.87 per share, a significant improvement from a $(0.38) loss YoY. However, the company missed sales estimates by 99.71%, reporting $80,000 in sales compared to the expected $27.66 million. The company exits the quarter with $273.8 million in cash and equivalents.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:08 am

DAY

Dayforce has announced its FY24 revenue guidance, projecting between $1.736 billion and $1.746 billion, slightly above the estimated $1.735 billion.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:08 am

TEVA

Teva Pharmaceutical has updated its 2024 adjusted EPS guidance to a range of $2.30-$2.50, up from the previous range of $2.20-$2.50, and above the consensus estimate of $2.34.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:08 am

SMG

Scotts Miracle-Gro shares are trading higher following better-than-expected Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:07 am